News and insights

Practice areas
Industries
1238 results
In the media
April 23rd, 2021

DataGuidance « Québec – Data Protection Overview | Guidance Note » to outline Québec's legal framework in terms of personal information protection

Langlois lawyers and partners Cynthia Chassigneux and Caroline Deschênes, who both have a special interest in personal information protection, contributed to the DataGuidance « Québec – Data Protection Overview | Guidance Note » to outline Québec's legal framework in terms of personal information protection
Awards and recognition
April 22nd, 2021

Canadian Legal Lexpert® Directory 2021

Langlois is pleased to announce that 22 of its lawyers have been named leading practitioners in the 2021 edition of the Canadian Legal Lexpert® Directory. The firm ranks itself among the best law firms in Québec.
Publications
April 21st, 2021

It’s the end of the work as we know it (and I feel fine)–or the importance of the concept of completion

The completion of the work, the correction of deficiencies and non-conformities, the handing over of the end-of-work documents and the taking possession of the work represent an important stage of a construction project. However, understanding the legal effects of the completion of the work and adopting effective contractual practices to that sense are often misunderstood […]
Publications
April 16th, 2021

Peace, order, good government and... climate change: the Supreme Court articulates the constitutional doctrine of the national concern

In 2018, in accordance with its international commitments, including the Paris Agreement, Parliament passed the Greenhouse Gas Pollution Pricing Act (the “GGPPA”). This legislative scheme has two components: (1) the creation of a fuel charge payable by certain producers, distributors and importers of various types of carbon-based fuels, and (2) the establishment of an output-based […]
Publications
April 15th, 2021

New ban on reimbursements affecting patient support programs

As of April 15, 2021, manufacturers, wholesalers and other intermediaries in the drug supply chain are subject to a new prohibition as a result of the enactment of the Regulation respecting exceptions to the prohibition against paying or reimbursing the price of a medication or supply covered by the basic prescription drug insurance plan1 (the “Regulation”). […]